Novo Nordisk (NYSE: NVO) has sparked investor interest primarily because of its weight loss treatments. Where to invest ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk (0QIU – Research Report) received a Hold rating and a DKK600.00 price target from Bernstein analyst Florent Cespedes today. The ...

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Novo Nordisk (NYSE: NVO) has found phenomenal success in treating patients with obesity and diabetes. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on Jan. 3, ...

So, despite its recent dip, Novo Nordisk remains an excellent pharmaceutical stock to buy and hold. AstraZeneca's strategy is different from Novo Nordisk's. Whereas the latter derives most of its ...